To investigate the clinical effect and safety of laparoscopic Roux-en-Y gastric bypass for the treatment of non-obese type 2 diabetesmellitus (T2DM).

The clinical data of 28 patients with T2DM performed LRYGB surgery between January 2016 and June 2017 in Guizhou Provincial People’s Hospital were analyzed. According to body mass index (BMI), these patients were divided into the non-obese group (11 cases, BMI≤27.5 kg/m²) and obese group (17 cases, BMI>27.5 kg/m²).The changes of fasting blood glucose (FPG), glycosylated hemoglobin (HbA1c), fasting C-peptide (FCp), fasting insulin (FIns) and complications were analyzed before and 3, 6, 9 and 12 months after operation.

All 28 cases were successfully operated. There were no significant differences in operation time or bleeding volume between the two groups (t=0.642, 0.871, P=0.526, 0.392). No serious complications occurred after operation. BMI, FPG, HbA1c, FCp and FIns in both groups showed a continuous downward trend with time, and the levels were significantly lower than those before operation (P<0.05). The level of FCp in non-obese group was significantly lower than that in obese group at 12 months after operation (t=0.711, P<0.05). The complete remission rates of T2DM in non-obese group and obese group were 72.7% (8/11) and 82.4% (14/17), respectively, with no significant difference (χ2=0.368, P=0.544).

LRYGB can significantly reduce BMI and improve glucose metabolism for non-obese T2DM, and the short-term postoperative safety is reliable.